-
BHQ: From SERCA Mechanism to Translation
2026-08-26
2,5-di-tert-butylbenzene-1,4-diol (BHQ) offers a mechanistic route from SERCA inhibition and calcium-store depletion to ER stress and hematopoietic stem cell mobilization. This thought-leadership guide connects calcium biology with translational study design while defining the compound’s opportunities, controls, and limitations.
-
(S)-Mephenytoin in Human CYP2C19 Translation
2026-08-26
Translational pharmacokinetics requires more than a clean enzyme assay: it requires a mechanistic bridge from catalytic activity to intestinal absorption, metabolism, and interindividual variability. This article positions (S)-Mephenytoin as a defined CYP2C19 substrate for building that bridge, then shows how recombinant systems, human pluripotent stem cell-derived intestinal organoids, and orthogonal analytical controls can be combined into a more decision-ready workflow.
-
URB597 (KDS-4103): Selective FAAH Inhibition
2026-08-25
URB597, also called KDS-4103, is a potent and selective FAAH inhibitor for experimental endocannabinoid research. It increases anandamide availability by blocking FAAH activity, with reported subnanomolar-to-low-nanomolar potency in neuronal systems and rapid in vivo FAAH inhibition in rats.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-25
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into two-dimensional intestinal epithelial monolayers containing metabolically active enterocytes, supporting more human-relevant pharmacokinetic studies.
-
Tianhuang Formula Targets RAGE/POMC in Metabolism
2026-08-24
This pre-proof study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and links RAGE/POMC signaling to hypothalamic neuronal apoptosis, autophagy, and glucolipid regulation. Its integrated computational, cellular, and mouse-model design provides a mechanistic framework for testing how neuronal homeostasis contributes to metabolic disease, while broader applications to neurodegeneration remain preliminary.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-24
The 2023 reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition to reduced renal fibrosis, inflammation, and epithelial–mesenchymal transition. Using AZ505 and LLY507 in animal and tubular epithelial-cell models, the authors connect these effects with altered Smad3, STAT3, and Smad7 signaling, while also defining important limits for translation.
-
Dimethyloxalylglycine (DMOG) Protocol Guide
2026-08-23
Dimethyloxalylglycine (DMOG), SKU A4506, provides a practical way to investigate hypoxia-inducible factor stabilization and related oxygen-sensing responses under normoxic culture conditions. It is intended for controlled in vitro and preclinical in vivo research, not for diagnostic, therapeutic, or medical use.
-
Mianserin HCl–Cyclodextrin Complexation
2026-08-22
The reference study shows that methylated β-cyclodextrin forms measurable host–guest complexes with mianserin hydrochloride but does not reduce its cytotoxicity in B14 cells. Its combined calorimetric, spectroscopic, mass-spectrometric, docking, and cell-based approach demonstrates why improved solubility should not be interpreted as improved biological safety.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-08-22
Tamoxifen is a versatile selective estrogen receptor modulator for conditional genetics, breast cancer research, and immune-oncology assays. This guide connects practical formulation and assay design with a recent study showing that tamoxifen can improve radiation responses by reprogramming tumor-associated macrophages.
-
Spermine Tetrahydrochloride in Translational Biology
2026-08-21
Spermine tetrahydrochloride is more than a polyamine additive: its charge-driven behavior connects membrane stabilization, protein crystallization, and polymer nanoparticle engineering. This thought-leadership article explains how translational researchers can use the reagent strategically, interpret the DDX3 structural biology precedent, and avoid overextending evidence into NMDA receptor or therapeutic claims.
-
Cefazedone (Refosporen) Research Workflows
2026-08-20
Cefazedone (Refosporen) supports reproducible broth-dilution, MIC, and time-dependent PK/PD workflows spanning Gram-positive and Gram-negative bacterial infections. This guide translates its solubility limits, exposure benchmarks, and clinical pharmacodynamic evidence into practical assay design and troubleshooting decisions.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow
2026-08-20
Build transient CRISPR-Cas9 experiments around Cap1-capped, m1Ψ-modified Cas9 mRNA for responsive editing in mammalian cells. This practical guide connects RNA handling, delivery, specificity testing, and the reference study’s mRNA-export insight to help distinguish poor delivery from excessive Cas9 exposure.
-
Tubastatin A: HDAC6 Inhibitor Workflows
2026-08-19
Tubastatin A links selective HDAC6 inhibition with microtubule stabilization, inflammatory control, and programmed-cell-death analysis. This practical guide translates porcine cardiac-arrest evidence into adaptable workflows for cancer biology, inflammation, neuroprotection, and cell-based mechanism studies.
-
Staurosporine and the Near-Death Metastasis Assay
2026-08-19
Staurosporine is more than an apoptosis trigger: it can help researchers separate acute kinase-dependent cell death from stable prometastatic states. This article translates recent PAME findings into practical assay and cancer research decisions.
-
Indometacin and Premature Ovulation in IVF
2026-08-18
This randomized, double-blind trial tested whether adding indometacin to modified natural-cycle IVF could reduce premature ovulation before oocyte retrieval. The overall difference was not statistically significant, but a prespecified clinical subgroup without an LH surge at human chorionic gonadotrophin administration showed a signal of benefit, supporting more selective rather than routine use in future studies.